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Open aca b s t r a c t
The authors present a case of a 53-years-old non-smoker Caucasian female who was diagnosed with lung
adenocarcinoma (stage IA) and underwent surgical resection in 2002. Five years later, the tumor relapsed
(stage IV disease) and she initiated chemotherapy with carboplatin, gemcitabine and bevacizumab as a
ﬁrst-line therapy. Despite partial remission after four cycles, this regimen was discontinued due to un-
acceptable toxicity. In 2008, the disease progressed and the patient was started on Erlotinib as second-
line treatment. The patient had a sustained partial remission which she maintains at present e 52
months after initiation of Erlotinib. Molecular testing performed on the primary lung tumor revealed an
Epidermal Growth Factor Receptor (EGFR) gene mutation (deletion in exon 19).
 2013 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
In Europe, non-small cell lung cancer (NSCLC) accounts for
approximately 85e90% of malignant lung neoplasms and this type
of cancer is more prevalent in males [1] but is increasing signiﬁ-
cantly in women [2]. According to an European forecast study for
2012, lung cancer will be the ﬁrst cause of death among women in
Poland and the United Kingdom [3].
Until 2009, platinum-based doublets chemotherapy was the
accepted standard of care for ﬁrst-line treatment of advanced
NSCLC. The response rate was 30% with a median progression-free
survival (PFS) and an overall survival (OS) of 6.4 and 10e12months,
respectively [4,5].
Since 2004, several studies have shown that patients with
Epidermal growth factor receptor (EGFR) mutations are the best
predictor of response to EGFR tyrosine kinase inhibitors (TKIs) such
as erlotinib and geﬁtinib [5], fact that has changed dramatically the
paradigm of advanced NSCLC treatment.
EGFR is a transmembranal glycoprotein detectable in 80e85% of
NSCLC which has a cytoplasmatic domain with TK activity [2,6].
Multiple ligands bind this receptor to initiate signal transduction
cascade leading to cell proliferation, antiapoptosis, angiogenesis,
invasion and metastasis [7]. Certain somatic mutations in the TK
domain of EGFR gene, mostly in exon 19 and 21 are “activating”,nçalves).
cess under CC BY-NC-ND license.meaning that binding of erlotinib or geﬁtinib to this domain pre-
vents cancer progression [5,6,8]. Such mutations are more frequent
among women, patients with adenocarcinoma, non-smokers and
East Asians individuals [5,9,10].
Currently, TKIs are considered the best ﬁrst-line of treatment for
patients EGFR-positive with advanced NSCLC, improving PFS and
quality of life with less toxicity [11,12] and also play an important
role in second-line setting with similar efﬁcacy to Docetaxel and
Pemetrexed but with the advantage of oral administration and
better tolerability [13].
Therefore, assessment of EGFR mutation status is crucial to
identify patients whowill respond to TKIs [14]. Furthermore, recent
studies have shown that EGFR expression is not stable during
metastatic progression, fact that has important clinical implications
and must be considered before starting this therapy [14].
Another emerging issue concerning TKI treatment is that most
patients with advanced NSCLC and activating EGFR mutations
experience marked improvement but eventually develop progres-
sion of disease within a median of 6e12 months [15,16].
2. Case report
In June 2002 a 53-yr-old Caucasian female was referred to our
Pulmonary Oncology consultation with a six-month history of
recurrent respiratory infections characterized by cough with
mucous sputum. She had no fever, chest pain or dyspnea and
also denied constitutional symptoms. Chest radiograph showed a
non-calciﬁed 2 cm nodule in the right upper lobe and chest CT scan
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apical segment of right upper lobe. She was a housewife, did not
have drinking or smoking habits, though she was a passive smoker.
She had undergone total hysterectomy with bilateral salpingo-
oophorectomy due to uterine ﬁbromiomatosis and had a history
of chronic constipation. She denied taking medication on a regular
basis and drug allergies. Her family history was unremarkable. On
physical examination, she was moderately obese (BMI 35.1 kg/m2),
hemodinamically stable and had no signs of respiratory distress (RR
16 cpm and SpO2 98% on room air). Cardiopulmonary auscultation
was normal as the remaining exam was unremarkable.
Because percutaneous transthoracic biopsy was technically
unfeasible, she underwent thoracic surgery. Extemporaneous his-
tological exam revealed lung adenocarcinoma with papillary
pattern areas and bilobectomy (right and middle lobe) was then
performed. Final pathological staging was pT1N0M0, stage IA.
In May 2007 despite asymptomatic, thoracoabdominal CT scan
showed diffuse pulmonary metastasis and a lobulated lesion in the
right lower lobe (RLL) (Fig. 1A). The patient was included in an
international multicenter trial and was started on carboplatin,
gemcitabine and bevacizumab every 3 weeks. Despite partial
remission after 4 cycles (Fig. 1B), therapy was discontinued due to
unacceptable hematologic toxicity.
One year later as thoracoabdominal CT scan revealed progres-
sive disease (Fig. 1C) we decided to send surgically resected tissue
for molecular testing. Evaluation of EGFRmutation, KRASmutation,
and ALK gene rearrangement were performed and revealed a
revealed a deletion in exon 19 (Del 2235-2249). The patient wasFig. 1. (A) Chest CT scan 5 years after surgery (2007). Signs of right upper and middle lobecto
right lower lobe (RLL) associated with bilateral micronodules. B) Chest CT scan after ﬁrst-l
reduction in number and size of pulmonary metastases. (C) Chest CT scan before Erlotinib (Ju
and irregular thickening of interlobular septa. (D) Chest CT scan after 52 months of Erlotinib
to July 2008 but stable in comparison to previous CT scan (not shown).started on oral Erlotinib (150 mg/day). By the second week of
treatment she developed a severe (grade 3) facial rash that
improved to grade 1 with oral doxycycline 100 mg and topical
treatment. At present she is asymptomatic and maintains partial
remission (Fig. 1D). Due to the excellent response and manageable
toxicity, our patient is still on treatment with Erlotinib after 52
months. In order to monitor treatment’s response and detect
possible side-effects, a clinical and imagiological (chest X-ray or
Chest CT scan) evaluation will be performed every month.
3. Discussion
Therapy of advanced NSCLC has changed dramatically after the
development of TKIs. Response to this therapy depends on the
presence of EGFR gene mutations in exons 19 and 21 [9,10]. In
Caucasians, these mutations predominate in females, non-smokers
and adenocarcinoma histology [5]. Considering both clinical and
histological characteristics of our patient, there was an increased
probability of EGFR mutation positivity.
A recent study showed that 50% of patients with EGFR
mutation-positive primary lung tumors lose the mutation in
metastasis and that discordance rate of EGFR expression between
primary tumor/metastases can reach 27% [14]. In view of current
knowledge, the analysis of EGFR mutation status in the primary
tumor may be inadequate for planning the use of TKIs for advanced
NSCLC, reason why tissue sampling from distant metastases must
be pursued to accurately determine EGFR mutations before treat-
ment [14]. Fortunately, although this procedure was not performed,my with mediastinal shift to the same side. Lobulated and irregular lesion located in the
ine chemotherapy (April 2008) showed residual densiﬁcation in the RLL and marked
ly 2008) e Numerous bilateral pulmonary nodules predominantly in subpleural spaces
(November 2012) eMarked reduction in number and size of lung metastasis compared
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static tumor harbors an EGFR-TKI-sensitive mutation. In addition,
there is some evidence that EGFR exon 19 deletion is associated
with better responses to erlotinib and longer survival compared to
exon 21 mutation [5,8] which suggests that exon 19 deletion might
still be present is our patient.
According to a large international multicenter study (TRUST),
unselected patients with advanced NSCLC who received erlotinib as
second-line therapy had amedian PFS and OS of 3.4 months and 8.6
months, respectively [17]. However, mutated Caucasian patients
have a better outcome, especially females [5]. According to Rosell
et al., median OS inwomen can achieve 29.0months vs 18.0months
in men (p¼ 0.05) and regarding PFS, it is also signiﬁcantly higher in
this gender (16.0 vs 9.0 months; p ¼ 0.003) [5]. Our patient is an
excellent example concerning efﬁcacy of erlotinib as a second-line
therapy in an EGFR-positive Caucasian female, since she has already
achieved a cumulative PFS of 52 months, which is extremely rare in
literature.
One important issue raised by this case concerns acquired resis-
tance to erlotinib. Recent data have shown that almost all patients
with known EGFR mutations who initially respond to TKIs, subse-
quently become resistant due to emergence of mutations, such as
T790M(in50%of cases) and c-METoverexpression [15,16]. Generally,
most tumors become resistance to TKIs within a median of 6e12
months [16] but this phenomenon has not occurred in our patient.
Our case strengthens the rationale for routine assessment of
EGFR mutations as it determines the best therapy for patients with
advanced NSCLC. Furthermore, it unequivocally shows that Erloti-
nib in an EGFR-positive patient with advanced NSCLC can provide
an excellent quality of life and a remarkable control of the disease
even as second-line treatment.
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